Navigation Links
SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
Date:1/6/2009

CALGARY, Jan. 6 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing protein pharmaceuticals in crop plants, today announced it has received US$2,500,000 from MannKind Corporation (Nasdaq: MNKD) as consideration for the option agreement and issuance of 2,400,000 units of SemBioSys, as previously announced December 24, 2008. The transaction provides MannKind with the option to the license rights to SemBioSys' proprietary plant-produced recombinant human insulin for use primarily in MannKind's ultra-rapid acting insulin, AFRESA(TM).

The units were issued at a price US$0.83 (Cdn$1.00) per unit. Each unit issued by SemBioSys consists of one common share of SemBioSys and one-tenth of one common share purchase warrant of SemBioSys. Each whole warrant entitles MannKind to purchase one additional common share of SemBioSys at an exercise price of Cdn$6.00 for a period of 36 months from the effective date of the option. The option period for the license rights ends on March 31, 2009.

About SBS Plant-Produced Insulin

SemBioSys' plant-produced insulin is human insulin produced from genetically enhanced safflower. SemBioSys has demonstrated that its plant-produced insulin is physically, structurally and functionally indistinguishable from pharmaceutical-grade human insulin through analytical testing and pre-clinical sub-chronic toxicology studies in rodents and primates. SemBioSys is currently conducting a Phase I/II clinical trial of its plant-produced insulin. The three-arm study, of up to 30 healthy volunteers, is designed to demonstrate the bioequivalence of safflower-produced insulin to two commercial insulin standards. Full results are expected to be available during the first half of 2009.

About SemBioSys

Calgary, Alberta-based SemBioSys is a biotechnology
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys begins phase I/II trial of insulin produced in plant seeds
2. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
3. SemBioSys announces second quarter 2008 financial and operational results
4. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
5. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
6. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
7. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
8. SemBioSys announces first quarter 2008 financial and operational results
9. SemBioSys receives milestone payments from AVAC Ltd.
10. SemBioSys initiates toxicology study for safflower-produced insulin
11. SemBioSys announces 2007 financial and operational results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
(Date:7/28/2015)... ZIONA, Israel , July 28, ... OTC:CQPTY), a regenerative medicine company utilizing its proprietary ... announced that Shomrat Shurtz has been appointed Senior ...      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) ... years of experience in marketing, regulatory and business ...
(Date:7/27/2015)... and FRANKLIN, Tenn. , July ... premier provider of health care services and one ... U.S., today announced that its parent company and ... definitive agreement with Medical Properties Trust, Inc. ("MPT") ... Capella for $900 million in cash.  The transaction is expected ...
(Date:7/27/2015)... ... July 27, 2015 , ... Production of high tenacity filament yarn of ... in the EU. For instance, it surpassed the EUR 106 million mark (in value ... 2010. Germany is a major producer, while Italy is a key consumer. , ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2
... an information technology and Web products and services provider ... announced today that St. Luke,s Hospital & Health Network ... remote 24/7/365 IT infrastructure monitoring from CareTech,s Healthcare Infrastructure ... and monitoring of data, systems and applications located in ...
... innovative medical imaging informatics company, today announced the commercial ... Edition. Following the April release of their first commercial ... commercial version of their widely accepted DICOM ImageServer software, ... With the release of the PACS, Team Edition, ...
... windows which, thanks to a nanocoating, adjust their level ... to save energy; novel diagnostic methods and tailor-made nano-medicines ... one hand, can be used to make very efficient ... pheromones, protect vineyards from insect attack; new nanostructured materials ...
Cached Biology Technology:St. Luke's Hospital & Health Network Selects CareTech Solutions to Provide Proactive Monitoring of Hospital IT Infrastructure 2St. Luke's Hospital & Health Network Selects CareTech Solutions to Provide Proactive Monitoring of Hospital IT Infrastructure 3ClearCanvas Releases First Commercial Version of Widely Used PACS; Integrated RIS/PACS to Follow 2A world without nano? Soon hard to imagine 2A world without nano? Soon hard to imagine 3
(Date:6/30/2015)... Pa. , June 30, 2015 ... the company as CEO to help further develop Genisphere,s ... wealth of partnering experience, having spent much of the ... including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. ... focus on Technology and Biotech Corporate Finance. He graduated ...
(Date:6/25/2015)... , June 25, 2015 ... Sensors Market by Type (Swipe & Area), Technology, Material ... Government, Healthcare, Commercial Security & Others) & Geography ... by marketsandmarkets, the said market is expected to ... of 17.1%. Browse 76 market ...
(Date:6/24/2015)... The biologics safety testing market is growing ... market include growth of the pharmaceutical and biological industries ... the years, the number of drug approvals in North ... FDA approved 225 drug applications and Health Canada approved ... accounted for 3,822 of the pharmaceutical and ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... 2008 American Society for Microbiology (ASM) Siemens ... presented to Adrian M. Zelazny, Staff Scientist, ... Institutes of Health (NIH). This award recognizes ... antimicrobial therapy. Dr. Zelazny is honored ...
... of supercomputers have hardware set up not just for ... seemingly random data. And now, a multi-institutional group of ... for these supercomputers. Applications include anywhere complex webs of ... grid stability to complex biological networks. The ...
... from infecting other cells and triggering their destruction by ... HIV-infected individuals but eventually peters out. To find out ... Infectious Diseases examined the cells that make the antibodies, ... that HIV gradually depletes the numbers of healthy, functional ...
Cached Biology News:Multithreaded supercomputer seeks software for data-intensive computing 2Multithreaded supercomputer seeks software for data-intensive computing 3
... cell-based assays utilize the membrane-permeant ester ... negatively charged fluorescent beta-lactamase substrates, CCF2 ... enter the cell, where cleavage by ... into their negatively charged forms, thereby ...
...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
...
Biology Products: